STAT3 and HIF1α Signaling Drives Oncogenic Cellular Phenotypes in Malignant Peripheral Nerve Sheath Tumors
- 13 July 2015
- journal article
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Research
- Vol. 13 (7) , 1149-1160
Abstract
Therapeutic options are limited for neurofibromatosis type 1 (NF1)-associated malignant peripheral nerve sheath tumors (MPNST) and clinical trials using drug agents have so far been unsuccessful. This lack of clinical success is likely attributed to high levels of intratumoral molecular heterogeneity and variations in signal transduction within MPNSTs. To better explore the variance of malignant signaling properties within heterogeneous MPNSTs, four MPNST cell lines (ST8814, S462, S1844.1, and S1507.2) were used. The data demonstrate that small-molecule inhibition of the MET proto-oncogene and mTOR had variable outcome when preventing wound healing, cell migration, and invasion, with the S462 cells being highly resistant to both. Of interest, targeted inhibition of the STAT3 transcription factor suppressed wound healing, cell migration, invasion, and tumor formation in all four MPNST lines, which demonstrates that unlike MET and mTOR, STAT3 functions as a common driver of tumorigenesis in NF1-MPNSTs. Of clinical importance, STAT3 knockdown was sufficient to block the expression of hypoxia-inducible factor (HIF)1α, HIF2α, and VEGF-A in all four MPNST lines. Finally, the data demonstrate that wound healing, cell migration, invasion, and tumor formation through STAT3 are highly dependent on HIF signaling, where knockdown of HIF1α ablated these oncogenic facets of STAT3.Keywords
All Related Versions
This publication has 35 references indexed in Scilit:
- Serum biomarkers for neurofibromatosis type 1 and early detection of malignant peripheral nerve-sheath tumorsBMC Medicine, 2013
- Conditional Inactivation ofPtenwithEGFROverexpression in Schwann Cells Models Sporadic MPNSTSarcoma, 2012
- Molecular heterogeneity in malignant peripheral nerve sheath tumors associated with neurofibromatosis type 1Human Genomics, 2012
- Combining EGFR and mTOR Blockade for the Treatment of Epithelioid SarcomaClinical Cancer Research, 2011
- Exploiting Cancer Cell Vulnerabilities to Develop a Combination Therapy for Ras-Driven TumorsCancer Cell, 2011
- Activated MET Is a Molecular Prognosticator and Potential Therapeutic Target for Malignant Peripheral Nerve Sheath TumorsClinical Cancer Research, 2011
- Transcriptional activation of the Axl and PDGFR-α by c-Met through a ras- and Src-independent mechanism in human bladder cancerBMC Cancer, 2011
- Phase II Study of Sorafenib in Patients With Metastatic or Recurrent SarcomasJournal of Clinical Oncology, 2009
- Survival in Malignant Peripheral Nerve Sheath Tumours: A Comparison between Sporadic and Neurofibromatosis Type 1-Associated TumoursSarcoma, 2009
- Guidelines for the diagnosis and management of individuals with neurofibromatosis 1Journal of Medical Genetics, 2006